A University of Colorado review clarifies what orthobiologics like PRP can and cannot do for joint healing, stressing symptom relief over cartilage repair.
On October 6, 2026, the University of Colorado Anschutz School of Medicine published a clinical discussion on orthobiologics. The article featured Jason Dragoo, MD, a professor of orthopedics. He serves as the medical director of UCHealth Steadman Hawkins Clinic Denver and head team physician for the Denver Nuggets. Dragoo explained how treatments like platelet-rich plasma are being studied for orthopedic healing. Most notably, he explicitly cautioned that platelet-rich plasma will not grow cartilage back.
Orthobiologics are treatments that use biological material to support the body in healing. The University of Colorado article names several specific types of these treatments. It highlights platelet-rich plasma and bone marrow aspirate concentrate as primary options. The discussion also names adipose-derived products used in clinical settings. These include stromal vascular fraction, microfragmented adipose tissue and nanofragmented adipose tissue.
The recent University of Colorado interview adds valuable nuance to how these specific therapies function. Dragoo described platelet-rich plasma as a preparation made by processing a patient's own blood. The laboratory process concentrates selected components before injecting them into an area of need. The intended goals are reducing inflammation and pain and improving the overall healing environment.
In the past, these biological injections were primarily known as exclusive therapies for professional athletes. The University of Colorado article notes that orthobiologics have now become much more common. They are increasingly used by recreational weekend warriors and everyday active adults. Patients managing chronic orthopedic conditions also frequently consider these options for symptom management. Conditions like long-term osteoarthritis often drive patients to seek out these newer alternatives.
Many individuals pursue these treatments hoping for complete joint regeneration or structural reversal. However, the goal of returning a joint to its original state often conflicts with biological reality. The interview explicitly tackled this common misconception regarding cartilage health. Dragoo cautioned that platelet-rich plasma will not grow cartilage back. The primary aim of these biological therapies remains symptom relief rather than structural reversal.
The sheer volume of these procedures provides researchers with substantial observational data. Dragoo says his laboratory performs more than 1,000 orthobiologic procedures annually. The center relies on its CURE Bank to study the biologics given to patients over time. By comparing biological samples with how patients fare, the team works to understand treatment effectiveness.
Dragoo emphasized that effective treatment and rigorous clinical research must go together. He stated that the clinic believes in effective treatment and making people feel better. At the same time, he noted that they believe research is just as important. The goal is to track treatment composition carefully to improve future medical outcomes.
The interview also addressed the timeline of expected benefits for patients undergoing these procedures. The publication says relief may last many months or sometimes years, according to Dragoo. However, the article does not provide condition-specific trial data to guarantee that duration. Dragoo suggested that chronic conditions such as arthritis might require repeat dosing over time. Conversely, an acute injury might be more likely to receive a one-time biological treatment.
The discussed treatments and ongoing studies target a specific population of orthopedic patients. Dragoo contrasted osteoarthritis and muscle injuries with issues like anterior cruciate ligament tears. He noted that established treatments already exist for these common ligament tears. Because of this, orthobiologics might be more worth considering for conditions without good conventional treatment options.
Patients should avoid assuming that results for one diagnosis automatically apply to another area. The medical field is still studying exactly how treatments work and which specific patients may respond. In the interview, Dragoo describes tracking treatment composition and patient outcomes through the CURE Bank. The team also studies tissue collected during orthopedic surgery to compare normal and abnormal tendon cells. This ongoing research underscores that individual patient responses can vary widely based on biology.
For active adults considering orthobiologics, this information highlights the need to manage expectations carefully. Patients must ask their clinical team exactly what outcome is being proposed for their specific diagnosis. You need to know if the target is less pain, reduced swelling or better daily function. A treatment might help a patient transition from rehabilitation exercises to hobbies by lowering pain barriers.
Understanding the difference between tissue healing and functional recovery can guide better conversations with your clinical team. You should ask your doctor how strong the evidence is for your particular joint condition. Always use these clinical discussions as a prompt for shared medical decision-making. Patients should focus on proven movement strategies rather than waiting for a complete biological reversal.
Biological injections should not be viewed as a standalone replacement for established physical rehabilitation. The University of Colorado publication does not compare orthobiologics against a defined physical therapy program. It also does not establish that an injection replaces the need for active muscular strengthening. Maintaining a standard rehabilitation program remains a critical component of rebuilding physical capacity. Orthobiologics may offer supportive relief, but they do not eliminate the need for functional movement work.
Despite the growing popularity of orthobiologics, several critical aspects of these treatments remain uncertain. The University of Colorado article omits several practical details that patients typically need for decision-making. The publication does not provide standard procedure prices or detailed insurance coverage expectations. It also lacks data on adverse-effect rates or specific medical contraindications. Patients must secure these details directly from their healthcare providers before proceeding.
The duration of potential relief is another area requiring careful patient consideration. Dragoo provides a general estimate of months or years in the published interview. However, the article does not supply condition-specific data to predict an individual patient's outcome accurately. Patients should treat claims about how long relief will last as highly individualized estimates. Assuming that a single injection will provide permanent relief is not supported by the cited interview data.
Finally, the ongoing nature of the research means clinical guidance will continue to change. The CURE Bank continues to study tissue and track outcomes to better understand tissue behavior. Biological joint treatments remain a developing area of medicine rather than a finalized standard of care. A careful, evidence-aware approach helps active adults make better choices during their recovery journey. Focus on manageable symptoms, clear functional milestones and open dialogue with your healthcare team.
Evaluating whether to pursue biological injections for persistent joint symptoms requires a realistic understanding of what these therapies can actually achieve. ReboundBody addresses the uncertainty about the transition from formal rehabilitation back to normal activity, helping you separate structural claims from established functional benefits. We provide the independent context needed to hold informed conversations with your medical team. Browse Resources
Follow ReboundBody for practical articles on injury recovery, rehabilitation, mobility and rebuilding strength. New posts turn research into clear ideas for the road back to activity after injury or surgery.
Read practical guidance on injury recovery, rehabilitation, mobility and rebuilding strength as you work your way back to activity.
Explore Resources